The Selective Protein Kinase C β Inhibitor Enzastaurin Induces Apoptosis in Cutaneous T-Cell Lymphoma Cell Lines through the AKT Pathway  by Querfeld, Christiane et al.
The Selective Protein Kinase C b Inhibitor Enzastaurin
Induces Apoptosis in Cutaneous T-Cell Lymphoma
Cell Lines through the AKT Pathway
Christiane Querfeld1,4, Mujahid A. Rizvi2, Timothy M. Kuzel2,4, Joan Guitart1,4, Alfred Rademaker3,4,
Simran S. Sabharwal4, Nancy L. Krett4 and Steven T. Rosen2,4
Enzastaurin displays pro-apoptotic properties against a spectrum of malignancies and is currently being
investigated in clinical trials. We have investigated the effects of enzastaurin on the viability of the cutaneous
T-cell lymphoma cell lines HuT-78 and HH by using 3-(4,5-dimethylthiazol-2-yl)-5(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium assay, cell cycle analysis, propidium iodide and annexin-V staining, and caspase-
3-mediated proteolytic activation. Enzastaurin-treatment decreased cell viability, increased annexin V-FITC-
positive cells, and increased the proportion of sub-G1 populations in both cell lines that was not reversed by the
T-cell growth stimulating cytokines IL-2, IL-7, IL-15. Enzastaurin-induced cell death involved caspase-3-activated
cleavage of poly(ADP-ribose) polymerase that was inhibited by the pan-caspase inhibitor ZVAD-fmk, whereas
the increase in sub-G1 population was only partially inhibited by ZVAD-fmk. Furthermore, enzastaurin
downregulated AKT activity and its downstream effectors GSK3b and ribosomal protein S6. The phosphatidy-
linositol 3-kinase (PI3K)/AKT pathway has been implicated in the growth and survival of hematologic
malignancies and inhibition of this pathway is considered as a therapeutic target. Protein kinase C activation
contributes to PI3K/AKT activation, but it is unknown how enzastaurin may interfere with signaling through this
pathway. These results demonstrate that enzastaurin, at clinically achievable concentrations, induces apoptosis
and affects AKT signaling, and provide a rationale for further in vivo studies addressing the therapeutic efficacy
in cutaneous T-cell lymphoma patients.
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INTRODUCTION
Primary cutaneous T-cell lymphomas (CTCLs) originate from
skin-homing T lymphocytes. Mycosis fungoides (MF) with
patch, plaque and/or tumor manifestations and the leukemic
variant Se´zary syndrome are the most common types and
account for 50% of all primary cutaneous lymphomas
(Querfeld et al., 2003). Mycosis fungoides has an indolent
course with slow progression over years; however, patients
ultimately progress into more aggressive and advanced
disease with either cutaneous or extracutaneous tumor
manifestations. At present, no curative therapy exists.
Systemic single-agent or multi-agent chemotherapies are
used to treat advanced and aggressive forms of CTCL to
palliate patients. Despite moderate response rates, however,
no treatment has been shown to prolong disease-free or
overall survival.
Protein kinase C (PKC) consists of a family of at least 11
serine-threonine protein kinases that are involved in signal
transduction pathways that regulate growth factor response,
proliferation, and apoptosis. T lymphocytes express the
classic PKC a and b isoforms, the novel isoforms PKC d, e,
Z, and y, and the atypical isoform PKC z (Mischak et al.,
1991; Altman et al., 2000). Members of the PKC family have
been shown to play an important role in T-cell activation and
proliferation (Sun et al., 2000; Long et al., 2001; Lisowska
et al., 2003) as well as to contribute to the growth and
survival of leukemic T cells (Villalba et al., 1999; Gorelik
et al., 2002; Felli et al., 2005). PKC b has been implicated in
hematologic malignancies such as B-cell lymphomas (Hans
et al., 2005), but its role in T-cell malignancies has not been
determined yet. Recently, it was found that PKC b is critical
for IL-2 secretion from the CTCL cell line HuT-78 (Long et al.,
2001). Keratinocyte-derived interferon-g-inducible protein 10
(IP-10) expression, promoting the epidermotropism of CTCL,
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has also been ascribed to PKC activation (Boorsma et al.,
1998).
Enzastaurin (LY317615), an acyclic bisindolylmaleimide,
is a selective orally administered PKC b inhibitor. It is
currently used in phase II trials for the treatment of refractory
glioblastoma and diffuse large B-cell lymphoma. Tumor-
induced angiogenesis requires the activation of PKC b and
enzastaurin was originally evaluated in human tumor xeno-
graft mice models for its antiangiogenic activity upon PKC b
inhibition (Keyes et al., 2004). However, in addition to its
antiangiogenic effects, enzastaurin, at concentrations reached
in clinical trials, directly suppressed proliferation and induced
apoptosis of tumor cells in culture and in human colon and
glioblastoma xenografts through the suppression of phosphory-
lation of AKT and its downstream effectors glycogen synthe-
tase kinase 3 beta (GSK3b) and ribosomal protein S6 (Fine
et al., 2005; Graff et al., 2005).
Based on these observations, we investigated the effect of
this PKC b inhibitor on the survival of two well-characterized
CTCL cell lines. In this study, we demonstrate that enzas-
taurin inhibits cell growth, induces partially caspase-depen-
dent apoptosis via specific inhibition of the AKT signaling
pathway in the CTCL cell lines HH and HuT-78.
RESULTS
Enzastaurin treatment suppresses tumor cell proliferation
and induces apoptosis in CTCL cells
To determine the effect of PKC bII inhibition to the survival
of HH and HuT-78 cells, we cultured these cell lines in the
presence of enzastaurin. HuT-78 and HH cells were treated
with 1, 2, 3, 4, and 5 mM enzastaurin and DMSO (vehicle
control) for 24, 48, 72, 120 hours and cell viability was deter-
mined by 3-(4,5-dimethylthiazol-2-yl)-5(3-carboxymethoxy-
phenyl)-2-(4-sulfophenyl)-2H-tetrazolium assay. There was
no significant cell growth inhibition at 24 and 48 hours (data
not shown). At 72 hours (Figure 1), treatment with enzastaurin
resulted in a dose-dependent inhibition of cell proliferation
(P¼0.002 for HuT-78; P¼ 0.005 for HH). However, HH
cells treated with 4 and 5 mM enzastaurin showed a signi-
ficantly higher number of viable cells compared to cells
treated with 1 to 3 mM doses suggesting a possible saturation
concentration for PKC inhibition in this cell line. The growth
inhibition in both cell lines was about 50%. At 120 hours a
60% growth inhibition was noted (data not shown).
To determine whether enzastaurin induces apoptosis as
evidenced by an increase in cells with a sub-G1 DNA content
and annexin V-binding, CTCL cell lines were treated with 1
and 3mM enzastaurin for 72 h. Using cell cycle analysis the
number of cells with sub-G1 populations treated with 3 mM
enzastaurin was significantly increased compared with
untreated control (P¼0.004 for HH; P¼0.003 for HuT-78),
indicating cells were undergoing apoptosis (Figure 2a and b).
The increase in sub-G1 populations was accompanied by
a loss of cells in the G1, S, and G2–M phases. In all, 1 mM
concentration of enzastaurin had no effects. The sub-G1 DNA
content was not reversed by the T-cell growth-stimulating
cytokines IL-2, IL-7, or IL-15 (data for IL-7 and IL-15 are not
shown).
In parallel to cell cycle analysis, the effect of enzastaurin on
annexin V-FITC-binding was investigated. The number of
annexin V-FITC-positive cells was significantly increased
compared with untreated control (Po0.0001) and is con-
sistent with the results of sub-G1 populations from propidium
iodide (PI) staining for cell cycle (Figure 2c and d). As a
positive control for annexin V binding, cells were treated with
10 mM 8-amino-adenosine (Krett et al., 2004).
Effect of enzastaurin on caspase activation and
poly(ADP-ribose) polymerase cleavage
Enzastaurin treatment for 72 hours increases the proportion of
sub-G1 populations in both cell lines. To determine whether
enzastaurin-induced cell death was caspase dependent, HH
and HuT-78 cells were treated with 40 mM of the pan-specific
caspase inhibitor ZVAD-fmk for 1 hour prior to exposure to
enzastaurin. Enzastaurin-induced cell death was partially
reversed after pretreatment with ZVAD-fmk (Figure 3a).
Furthermore, immunoblotting analysis showed caspase-3
activation, revealing a specific proteolytic cleavage of the
caspase substrate poly(ADP-ribose) polymerase (PARP) from
116 to 85 kDa (Figure 3b). Cleavage occurred at 24 hours
of drug treatment. Equal amounts of total protein from
enzastaurin-treated HuT-78 cells were analyzed separately
and showed similar results (data not shown). Cleavage of
PARP was prevented if cells were preincubated with ZVAD-
fmk (Figure 3c) indicating that caspase activity is at least
partially required for enzastaurin-induced cell death.
Enzastaurin decreases GSK3b protein, phosphorylation
of GSK3b and ribosomal protein S6
PKC activation has been linked to the AKT pathway that plays
a critical role in cell survival and apoptosis. Enzastaurin was
reported to block AKT activity through inhibition of PKC b. By
immunoblotting, there was no enzastaurin-stimulated change
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Figure 1. Effect of enzastaurin on cell viability. HH and HuT-78 cells were
exposed to 1, 2, 3, 4, and 5 mM enzastaurin or DMSO (vehicle control) for
72 hours. Treated and untreated cells were subjected to the 3-(4,5-
dimethylthiazol-2-yl)-5(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tet-
razolium assay. Results are expressed as the percentage of the untreated
control (mean7SD, n¼ 4; P¼ 0.005 for HH; P¼ 0.002 for Hut-78;
*significantly lower compared to vehicle control value).
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in phosphorylated PKC b levels (Figure 4a). We investigated
the changes in AKT phosphorylation after exposure to 3 mM
enzastaurin for 0.5, 1 hour, 2, 4, and 24 hours. Enzastaurin
decreased AKT phosphorylation at 0.5 hours persisting
through 24 hours (Figure 4b). To confirm the inhibition of
AKT kinase, we examined the phosphorylation status of 2
downstream AKT substrates, GSK3b and ribosomal protein
S6. In general, phosphorylated/activated AKT maintains a
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Figure 2. Enzastaurin treatment increases sub-G1 populations and annexin V binding in HH and HuT-78 cells. (a) Cells were treated with 1 and 3 mM
enzastaurin and/or IL-2 for 72 hours. Cell cycle was analyzed by PI staining and flow cytometry (*P¼ 0.004 for HH; P¼ 0.003 for Hut-78). (b) Corresponding
histograms for cell cycle analysis. (c) Annexin V binding was carried out with the Annexin V-FITC Detection Kit. As a positive control for annexin V binding,
HH cells were treated with 10 mM 8-amino-adenosine (*Po0.0001; data for HuT-78 not shown). (d) Representative flow cytograms. All the data in (a) and
(c) are presented as means7SD of three representative experiments.
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pro-survival pathway by preventing apoptosis through phos-
phorylation and inactivation of pro-apoptotic proteins such as
GSK3b. Enzastaurin treatment suppressed active phosphory-
lated GSK3b levels (Figure 4c). Immunoblot analysis showed
a reproducible reduction at 30 minutes, persisting through
72 hours after treatment with enzastaurin. Ribosomal protein
S6 is another downstream effector of AKT signaling, critical
for protein synthesis. Enzastaurin also decreased the phos-
phorylation of ribosomal protein S6 in a time-dependent
fashion (Figure 4d).
DISCUSSION
Enzastaurin has been shown to inhibit cell growth and induce
apoptosis in various cultured human tumor cell lines and
tumor xenografts (Teicher et al., 2001a, b, 2002; Keyes et al.,
2004; Graff et al., 2005). In this study, enzastaurin effectively
inhibited growth and induced apoptosis in two well-charac-
terized human CTCL cell lines, HH cells, and HuT-78 cells,
with evidence of a time- and dose-dependent manner.
Apoptosis was measured by increased annexin V-binding
and cleavage of cellular components such as PARP and DNA.
Exposure of these cell lines to ZVAD-fmk did only par-
tially reduce apoptosis upon treatment with enzastaurin, but
did prevent PARP cleavage. The data further indicate that
enzastaurin-induced apoptosis appears partially caspase
mediated.
Both the serine/threonine PKC and AKT subfamilies have
been implicated in signaling pathways leading to activa-
tion, differentiation, and cell survival of T lymphocytes. AKT
is mainly activated by the upstream phosphatidylinositol
3-kinase (PI3K) and deregulated PI3K/AKT signaling in
oncogenic transformation and cancer progression has been
reported (Vivanco and Sawyers, 2002). The PI3K/AKT path-
way was reported to be particularly important for the growth
and survival of acute lymphoblastic T-cell leukemia cell lines
deficient for the PI3K-antagonistic enzyme PTEN (Uddin
et al., 2005). Apoptosis induced by PI3K inhibition correlated
with AKT dephosphorylation in contrast to the PTEN-expres-
sing HuT-78 CTCL cell line. Various models have also shown
that enhanced PI3K/AKT-signaling pathway in T cells triggers
lymphoid hyperplasia and autoimmunity (Di Cristofano et al.,
1999). The proto-oncogene human T-cell prolymphocytic
leukemia 1 was found to be an AKT kinase coactivator (Laine
et al., 2000).
AKT activation requires the recruitment of the enzyme to
the plasma membrane by interacting with membrane-bound
lipid products of PI3K. Phosphorylation of both threonine
(Thr308) and serine (Ser473) residues fully activates AKT,
which maintains a survival signal that protects cells from
apoptosis by phosphorylating pro-apoptotic proteins such as
caspase-9, Bad, and the Forkhead family of transcription
factors, the cell regulatory protein GSK3b, and indirectly by
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Figure 3. Effect of enzastaurin on caspase activation and PARP cleavage.
HH cells were incubated with 3 mM enzastaurin for the indicated times with
or without preincubation with 40mM ZVAD-fmk for 1 hour. (a) Quantification
of cell-cycle distribution in HH cells was analyzed by PI staining and flow
cytometry (mean7SD, n¼2). (b and c) Total cell extracts were subjected to
immunoblot analysis for caspase-3 mediated proteolytic activation using an
antibody specific for PARP. For all studies, similar results were obtained from
three independent experiments. Total protein levels were assessed to ensure
equal loading and transfer.
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Figure 4. Enzastaurin suppresses cell signaling within the AKT pathway. HH
cells were exposed to 3 mM enzastaurin in RPMI supplemented with 1% fetal
bovine serum for the indicated times. Immunoblot analyses were performed
with using antibodies specific for (a) PKCb II, (b) AKT, (c) GSK3b, and (d) RP
S6. GAPDH expression was used to ensure equal loading and transfer.
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cell proliferative modulating p53 and NF-kB (Cardone et al.,
1998; Pap and Cooper, 1998; Khwaja, 1999; Shankar et al.,
2004) and mediates growth factor-induced cell proliferation
(Chang et al., 2003). Recent studies done by Graff et al.
(2005) emphasized the importance of the PI3K/AKT signaling
pathway in enzastaurin-induced apoptosis in human cancer
cell lines. In our study, expression of phosphorylated AKT
was also decreased by enzastaurin treatment. Downregula-
tion was apparent at 30 minutes. We further analyzed the
enzastaurin effect on AKT downstream targets. Both cell lines
showed a marked decrease in phosphorylated GSK3b and
RP S6 levels at 30 minutes of drug treatment. AKT was
suppressed in CTCL cell lines within 30 minutes and further
indicates that enzastaurin inhibits GSK3b and RP S6 activity
by AKT downregulation.
Several PKC isoforms are known to interfere with PI3K/
AKT activity in T lymphocytes. In the myeloid HL-60 leuke-
mia cell line, a potential role of PKC b in tumor necrosis
factor-a-induced apoptosis has been reported (Laouar et al.,
1999). PKC y was identified to protect T lymphocytes from
Fas-induced apoptosis (Villalba et al., 1999). PKC-dependent
p90 ribosomal S6 kinase phosphorylation promoted cell
survival through phosphorylation and inactivation of the pro-
apoptotic Bcl-2 family member Bad (Bertolotto et al., 2000).
Enzastaurin impairs PI3K/AKT signaling, but the pathway
remains to be elucidated. It is thought to selectively inhibit
PKC b at low concentrations, but inhibits other PKC isozymes
at concentrations reached in clinical trials (1–4 mM). There-
fore, it is feasible that inhibition of the AKT-signaling pathway
may be influenced by enzastaurin-induced effects on other
PKC isoforms.
CTCL is a slowly progressive malignancy for which there is
no cure and patients ultimately develop advanced or relapsed
disease that is refractory to standard treatment options. No
treatment has been shown to prolong disease-free or overall
survival and therefore, there is a great need for the develop-
ment of novel emerging therapies. It appears that enzastaurin-
induced AKT suppression affects both caspase-mediated
apoptosis and cell cycle regulatory pathways, but may involve
various biochemical mechanisms. The results of this study
provide a rationale for further evaluation of enzastaurin as a
potential therapeutic agent for CTCL. Inhibition of the PI3K/
AKT pathway prevents uncontrolled proliferation and enzas-
taurin has shown to downregulate this pathway, however, the
overall role of PKC in CTCL needs to be elucidated.
MATERIALS AND METHODS
Cell culture and reagents
The CTCL cell lines HuT-78 and HH were obtained from the
American Type Culture Collection (ATCC, Manassas, VA) and were
grown in RPMI 1640 (Invitrogen, Baltimore, MD) supplemented with
10% fetal bovine serum, 2 mM glutamine, 100 U/ml penicillin,
100mg/ml streptomycin, and 2.5mg/ml amphotericin B. Cells were
maintained at 371C in a humidified atmosphere containing 5% CO2.
HuT-78 phenotype (CD2, CD3þ dim, CD4þ , CD5þ , CD7þ dim,
CD8, CD25, CD26, CD52) and HH phenotype (CD2,
CD3þ dim, CD4þ , CD5þ , CD7þ partial dim, CD8, CD25, CD26,
CD52) was established by flow cytometry.
Enzastaurin was a gift from Eli Lilly & Co (Indianapolis, IN).
Stock solutions of 10 mM were prepared in DMSO and stored at
201C. IL-2, IL-7, IL-15, and the pan-specific caspase inhibitor
ZVAD- fluoromethylketone (ZVAD-fmk) were purchased from R&D
Systems (Minneapolis, MN). Enzastaurin has a high protein-binding
affinity and to achieve clinically relevant concentrations in each
experiment RPMI 1640 containing 1% fetal bovine serum was used.
The final DMSO concentration in all experiments was o0.001%.
Polyclonal antibodies against the phosphorylated/activated form
of PKC-bII, GSK3b (pS9), and ribosomal protein S6 (pS240/244)
and against total S6 ribosomal protein, and AKT were purchased
from Cell Signaling Technologies (Beverly, MA). Antibody directed
against phosphorylated AKT (pS473) was obtained from R&D
Systems (Minneapolis, MN). Antibody to total PKC-bII was pur-
chased from Santa Cruz Biotechnology (Santa Cruz, CA). Total
GSK3b antibody and PARP monoclonal antibody were obtained
from BD Pharmingen (San Diego, CA).
Cell proliferation assay
Cells were seeded at a density of 2.5 104 cells per well in a 96-well
tissue plate and were treated with enzastaurin, DMSO (vehicle), IL-2,
IL-7, or IL-15 for 72 hours in a total volume of 100 ml RPMI with 1%
fetal bovine serum. Cell viability and growth was determined using
the 3-(4,5-dimethylthiazol-2-yl)-5(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium Cell Titer Assay (Promega, Madison,
WI) that measured the conversion of a tetrazolium compound into
formazan spectrophotometrically. The quantity of formazan product
as measured by the amount of 490 nm absorbance is directly
proportional to the number of living cells in culture. The data are
expressed as percentage of untreated control cells. Each condition
was performed in quadruplicate and all experiments were performed
at least three times. Each data point represents the mean value
(percentage)7SE.
Immunoblotting analysis
Cells were seeded in 25 cm2 cell culture flasks at a density of 5 106
cells/flask and allowed to grow overnight in RPMI containing 1%
fetal bovine serum. After 24 hours cells were treated with 3 mM
enzastaurin for the indicated times, harvested, washed with ice-cold
phosphate-buffered saline (PBS), and lysed in protein lysis buffer
(50 mM N-[2-hydroxyethyl]piperazine-N0-[2-ethanesulphonic acid]
(HEPES), 10% glycerol, 0.5% Triton X-100, 150 mM NaCl, 1.5 mM
MgCl2, 1 mM EDTA, pH 8.0, 100 mM NaF, 10 mM sodium pyrophos-
phate, 500mM phenylmethylsulfonyl fluoride, 200 mM sodium ortho-
vanadate, and 10 mg/ml aprotinin) at 41C for 1 hour. Lysates were
centrifuged at 10,000 g at 41C for 1 minute and the supernatants
were collected in 1.5-ml microcentrifuge tubes and stored at 201C.
Protein concentration was determined by BioRad protein assay
(BioRad Laboratories, Hercules, CA). Protein at a concentration
of 30mg was fractionated on a precast 8–16% Tris-glycine gel
(Invitrogen, Carlsbad, CA) and subsequently transferred to a
polyvinylidene fluoride membrane. The membranes were incubated
with 5% nonfat milk diluted in Tris-buffered saline (10 mM Tris (pH
7.4), 150 mM NaCl, 0.1% Tween 20) for 1 hour to block nonspecific
binding and were then incubated with the appropriate primary
antibodies overnight at 41C. The blots were then washed with Tris-
buffered saline for 15 minutes and incubated with horseradish
peroxidase–conjugated secondary antibody (Amersham, Arlington
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Heights, IL) for 1 hour. Antibody binding was detected using
Enhanced Chemiluminescence Plus Western Blotting Detection
Reagent (Amersham) and the signal was visualized with X-ray film
(Hyperfilm, Amersham).
Cell cycle analysis
Cells were grown in 25 cm2 flasks at a concentration of 1 106
cells/ml and treated with 3 mM enzastaurin and indicated cytokines.
To determine the distribution of cells within the cell cycle, cells were
collected after 72 hours, centrifuged (500 g for 5 minutes at 41C),
washed twice in ice-cold PBS, fixed in ice-cold 40% ethanol, and
stored at 41C until analyzed. Before flow cytometry analysis, the
fixed cells were washed in PBS, treated with 50 mg/ml DNase-free
RNase in PBS, and incubated for 30 minutes at 371C. The samples
were then resuspended in 25 mg/ml PI in 38 mM sodium citrate buffer.
Flow cytometry was performed on a Coulter EPICs XL instrument,
and data were analyzed using the System II software package. To
determine whether enzastaurin-induced apoptosis was caspase
dependent, cells were pretreated with the pan-specific caspase
inhibitor ZVAD-fmk for 1 hour prior to enzastaurin treatment at
a final concentration of 40 mM.
Annexin V staining
Cells (1 106/ml) were treated with 3mM enzastaurin and harvested
after 72 h. As cells undergo apoptosis, the integrity of the cell
membrane is disrupted and phosphatidylserine is exposed. Detec-
tion of phosphatidylserine on the outer leaflet of apoptotic cells was
performed by using annexin V binding according to the manufac-
turer’s instructions (BD Pharmingen, San Diego, CA). Briefly, cells
were incubated with 5mg/ml FITC-conjugated annexin V in the
presence of 5 mg/ml PI and further screened by flow cytometry
(Coulter EPICs XL). Annexin V-FITC-positive PI-negative cells were
scored as early apoptotic. Annexin V-positive PI-positive cells
correspond to late apoptotic cells. As a positive control for apoptosis,
cells were treated with 10 mM of the purine nucleoside analogue,
8-amino-adenosine.
Statistical analysis
Data were analyzed using one-way analysis of variance with
post hoc t-tests adjusted for multiple comparisons at Po0.05 using
Tukey’s method (Figures 1 and 2a), and the two-factor analysis of
variance test for interaction (Figure 2b). Statistical analyses were
carried out using the SAS statistical software (SAS Institute Inc., SAS
OnlineDocs, Version 9.1, Cary, NC: SAS Institute Inc., 2003).
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